ASO Author Reflections: Outcome Improvement Over Time in Extremity and Trunk Wall Soft Tissue Sarcomas: To Whom the Merit?

[1] Gronchi A(2011)Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution Ann Oncol. 22 1675-1681

[2] Miceli R(2022)Refining the approach to patients with primary soft tissue sarcoma of the extremities and trunk wall: outcome improvement over time at a single institution Ann Surg Oncol. 17 671-680

[3] Colombo C(2016)Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis Lancet Oncol. 128 85-93

[4] Danieli M(2022)Neoadjuvant chemotherapy in high risk soft tissue sarcomas: a sarculator-based risk stratification analysis of the randomized trial ISG-STS 1001 Cancer. 32 1348-1365

[5] Barretta F(2021)Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol. undefined undefined-undefined

[6] Fiore M(undefined)undefined undefined undefined undefined-undefined

[7] Callegaro D(undefined)undefined undefined undefined undefined-undefined

[8] Miceli R(undefined)undefined undefined undefined undefined-undefined

[9] Bonvalot S(undefined)undefined undefined undefined undefined-undefined

[10] Pasquali S(undefined)undefined undefined undefined undefined-undefined

[1] Gronchi A(2011)Primary extremity soft tissue sarcomas: outcome improvement over time at a single institution Ann Oncol. 22 1675-1681

[2] Miceli R(2022)Refining the approach to patients with primary soft tissue sarcoma of the extremities and trunk wall: outcome improvement over time at a single institution Ann Surg Oncol. 17 671-680

[3] Colombo C(2016)Development and external validation of two nomograms to predict overall survival and occurrence of distant metastases in adults after surgical resection of localised soft-tissue sarcomas of the extremities: a retrospective analysis Lancet Oncol. 128 85-93

[4] Danieli M(2022)Neoadjuvant chemotherapy in high risk soft tissue sarcomas: a sarculator-based risk stratification analysis of the randomized trial ISG-STS 1001 Cancer. 32 1348-1365

[5] Barretta F(2021)Soft tissue and visceral sarcomas: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up Ann Oncol. undefined undefined-undefined

[6] Fiore M(undefined)undefined undefined undefined undefined-undefined

[7] Callegaro D(undefined)undefined undefined undefined undefined-undefined

[8] Miceli R(undefined)undefined undefined undefined undefined-undefined

[9] Bonvalot S(undefined)undefined undefined undefined undefined-undefined

[10] Pasquali S(undefined)undefined undefined undefined undefined-undefined